Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
Public ClinicalTrials.gov record NCT01734785. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy.
Study identification
- NCT ID
- NCT01734785
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Enrollment
- 607 participants
Conditions and interventions
Conditions
Interventions
- Linagliptin Drug
- Empagliflozin + Linagliptin Drug
- Empagliflozin placebo + Linagliptin placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 7, 2013
- Primary completion
- Mar 22, 2015
- Completion
- Mar 22, 2015
- Last update posted
- Sep 18, 2024
2013 – 2015
United States locations
- U.S. sites
- 28
- U.S. states
- 15
- U.S. cities
- 27
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1275.9.01013 Boehringer Ingelheim Investigational Site | Gulf Shores | Alabama | — | — |
| 1275.9.01009 Boehringer Ingelheim Investigational Site | Norwalk | California | — | — |
| 1275.9.01015 Boehringer Ingelheim Investigational Site | San Diego | California | — | — |
| 1275.9.01017 Boehringer Ingelheim Investigational Site | San Diego | California | — | — |
| 1275.9.01011 Boehringer Ingelheim Investigational Site | Northglenn | Colorado | — | — |
| 1275.9.01010 Boehringer Ingelheim Investigational Site | Coral Gables | Florida | — | — |
| 1275.9.01004 Boehringer Ingelheim Investigational Site | Miami | Florida | — | — |
| 1275.9.01006 Boehringer Ingelheim Investigational Site | Oldsmar | Florida | — | — |
| 1275.9.01001 Boehringer Ingelheim Investigational Site | Palm Coast | Florida | — | — |
| 1275.9.01027 Boehringer Ingelheim Investigational Site | Port Orange | Florida | — | — |
| 1275.9.01029 Boehringer Ingelheim Investigational Site | Blue Ridge | Georgia | — | — |
| 1275.9.01003 Boehringer Ingelheim Investigational Site | Marietta | Georgia | — | — |
| 1275.9.01022 Boehringer Ingelheim Investigational Site | Savannah | Georgia | — | — |
| 1275.9.01031 Boehringer Ingelheim Investigational Site | Chicago | Illinois | — | — |
| 1275.9.01019 Boehringer Ingelheim Investigational Site | Methuen | Massachusetts | — | — |
| 1275.9.01024 Boehringer Ingelheim Investigational Site | Troy | Michigan | — | — |
| 1275.9.01023 Boehringer Ingelheim Investigational Site | St Louis | Missouri | — | — |
| 1275.9.01002 Boehringer Ingelheim Investigational Site | Omaha | Nebraska | — | — |
| 1275.9.01007 Boehringer Ingelheim Investigational Site | Newington | New Hampshire | — | — |
| 1275.9.01016 Boehringer Ingelheim Investigational Site | Asheboro | North Carolina | — | — |
| 1275.9.01025 Boehringer Ingelheim Investigational Site | Burlington | North Carolina | — | — |
| 1275.9.01014 Boehringer Ingelheim Investigational Site | Shelby | North Carolina | — | — |
| 1275.9.01028 Boehringer Ingelheim Investigational Site | Winston-Salem | North Carolina | — | — |
| 1275.9.01018 Boehringer Ingelheim Investigational Site | Dayton | Ohio | — | — |
| 1275.9.01005 Boehringer Ingelheim Investigational Site | Corvallis | Oregon | — | — |
| 1275.9.01032 Boehringer Ingelheim Investigational Site | Corpus Christi | Texas | — | — |
| 1275.9.01030 Boehringer Ingelheim Investigational Site | Houston | Texas | — | — |
| 1275.9.01021 Boehringer Ingelheim Investigational Site | San Antonio | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 62 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01734785, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 18, 2024 · Synced Jul 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01734785 live on ClinicalTrials.gov.